Welcome to our dedicated page for IceCure Medical news (Ticker: ICCM), a resource for investors and traders seeking the latest updates and insights on IceCure Medical stock.
IceCure Medical Ltd. develops and markets liquid-nitrogen-based cryoablation systems for minimally invasive tumor destruction. Its flagship ProSense® system is used for benign and cancerous lesions, with company updates centered on breast, kidney, bone and lung cancer indications and on markets where the device is cleared or approved, including the United States, Europe and Asia.
News about ICCM commonly covers ProSense commercialization, FDA-related breast cancer developments, post-market study activity, clinical evidence such as the ICESECRET kidney cancer study, medical-conference presentations, financial and operating results, and governance changes. The company’s updates also address physician training, reimbursement context and shareholder matters tied to its ordinary shares.
IceCure Medical (NASDAQ: ICCM) announced that its distributor in Brazil, KTRFIOS, has submitted a regulatory filing to the Brazilian Health Regulatory Agency (ANVISA) for the ProSense system. The application targets multiple cancer treatments including breast and prostate cancer, with KTRFIOS guaranteeing at least $6.6 million in sales within five years of approval. Brazil's rising cancer incidence underscores the demand for innovative treatments. CEO Eyal Shamir highlighted this milestone as pivotal for expanding IceCure's global regulatory landscape, which spans 14 countries including the U.S. and Europe.
IceCure Medical Ltd. (NASDAQ: ICCM) reported Q1 2022 revenues of approximately $0.75 million, a 48% decline from $1.4 million in Q1 2021, primarily due to decreased revenue from distribution agreements and lower sales in Asia amidst COVID restrictions. Gross profit was approximately $0.43 million, with a gross margin of 58%. Operating expenses rose to $4.9 million, resulting in a net loss of $4.4 million ($0.12 per share). Despite these challenges, IceCure saw increased commercial activity and plans to further develop its ProSense® System for breast cancer treatment.
IceCure Medical (NASDAQ: ICCM) is set to release its financial results for Q1 2022 on May 18, 2022, at 7:00 am ET. The announcement will be followed by a conference call at 8:30 am ET, featuring Dr. Richard Fine, discussing the ProSense® System, a cryoablation technology for treating tumors. IceCure specializes in minimally invasive treatments for various cancers, including breast, kidney, and lung cancers. The conference call can be accessed via US and international lines provided in the announcement.
IceCure Medical (NASDAQ: ICCM) announced its participation in the European Conference on Interventional Oncology (ECIO) from April 24-27, 2022, showcasing its ProSense® cryoablation system. The event featured a symposium led by Professor Franco Orsi, highlighting cryoablation's effectiveness for renal and adrenal cancers. Interim results from the ICE3 trial revealed a 98% recurrence-free rate in patients treated for low-risk breast cancer. The company aims to expand ProSense®'s regulatory approvals and establish it as a premier cryoablation option globally.
IceCure Medical Ltd. (NASDAQ: ICCM) reported preliminary unaudited revenue of $4.1 million for 2021, up from $3.9 million in 2020, primarily driven by sales from distribution agreements in Europe and the U.S. ProSense® system. Cash and equivalents surged to $25.6 million from $3.5 million in the prior year, aided by $32 million in equity raises. The company plans to enhance its regulatory and commercial strategies in the U.S., China, and Japan and pursue further FDA approvals for breast cancer treatments.
IceCure Medical Ltd. (NASDAQ: ICCM) shared a letter to shareholders reflecting on its achievements in 2021 and outlining objectives for 2022. The company reported positive interim results from the ICE3 clinical trial and noted progress in gaining regulatory approvals in the U.S., China, and Japan. IceCure also successfully raised $32 million in funding and expanded its global distribution network. Looking ahead, the focus will be on commercialization, regulatory clearances, and the development of next-generation cryoablation systems. The company expressed gratitude to its shareholders for their support.
IceCure Medical Ltd. (NASDAQ: ICCM) announced receiving notification from the European Patent Office of an intention to grant a patent for its proprietary cryogenic pump, which will enhance the ProSense® cryoablation system. This pump is designed for long-term procedures without the need for frequent liquid nitrogen refills, improving efficiency and temperature control. The patent will be effective until 2041. CEO Eyal Shamir highlighted its potential to enhance cryoablation procedures and expand treatment applications.
IceCure Medical Ltd. (NASDAQ: ICCM) announced the closing of its underwritten public offering, raising approximately $17 million by selling 3,892,152 shares at $3.45 each, including an over-allotment of 578,325 shares. Additionally, pre-funded warrants for 1,034,000 shares were offered at $3.449 each. The funds will be utilized for product development, business development, working capital, and general corporate purposes.
IceCure Medical Ltd. (NASDAQ: ICCM) announced a public offering of 3,313,827 shares at $3.45 each, aiming to raise approximately $15 million. The offering includes pre-funded warrants to purchase 1,034,000 shares, priced at $3.449 each. Expected to close by December 13, 2021, the funds will support product development, business growth, and general corporate purposes. A.G.P./Alliance Global Partners is the book-running manager for the offering.
IceCure Medical (NASDAQ: ICCM) announced that interim data from its ICE3 Clinical Trial on cryoablation for small, low-risk breast cancer was presented by Dr. Kenneth Tomkovich at the RSNA meeting, which took place from November 29 to December 2, 2021. Dr. Tomkovich's presentation highlighted the growing acceptance of cryoablation as a treatment option. IceCure's CEO, Eyal Shamir, noted that this recognition supports the promising ICE3 data. The ProSense® System offers a minimally-invasive alternative to surgical tumor removal, focusing on effective treatment options for various cancers.